ICR Reveals New Courses on EU Regulation & Line Management
ICR has announced two new courses for December 2014 about the impact of the European Union regulation and essential line management.
The Institute of Clinical Research (ICR) has announced two new courses for December 2014 about the impact of the European Union regulation and essential line management. The former event is scheduled for December 9, while the latter will take place on December10-11.
Other eye-catching training sessions being organized by ICR are on skills and competencies of a clinical trials manager (October 9-10), effective clinical trial management (November 11-13), and essentials of clinical trials monitoring (November 25).
ICR is a not-for-profit organization that provides education and training, conferences and networking events, and news updates and analysis on all aspects of clinical research. Members are engaged in all aspects of work in clinical research, both directly and in the support services. It was founded in 1978 as ACRPI (Association of Clinical Research for the Pharmaceutical Industry), and changed its name to ICR in 2000. Its head office is in Maidenhead, Berkshire, U.K., and it has over 3000 members in 49 countries around the world.
For further details, contact icrenquiries@yahoo.co.uk or visit http://www.icr-global.org/home/.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
